MiRNA-based therapeutic potential in multiple sclerosis

A Zabalza, A Pappolla, M Comabella… - Frontiers in …, 2024 - frontiersin.org
This review will briefly introduce microRNAs (miRNAs) and dissect their contribution to
multiple sclerosis (MS) and its clinical outcomes. For this purpose, we provide a concise …

MicroRNA Frontiers: Illuminating Early Detection Paths in Multiple Sclerosis

M Mohseni, G Behzad, A Farhadi, J Behroozi… - Multiple Sclerosis and …, 2024 - Elsevier
Multiple sclerosis (MS) manifests as progressive disability stemming from the demyelination
of axons within the central nervous system, resulting in neuronal loss and atrophy in the …

Multiple sclerosis disease activity, a multi-biomarker score of disease activity and response to treatment in multiple sclerosis

A Tatomir, F Anselmo, D Boodhoo, H Chen… - Frontiers in …, 2024 - frontiersin.org
Regular assessment of disease activity in relapsing-remitting multiple sclerosis (RRMS) is
required to optimize clinical outcomes. Biomarkers can be a valuable tool for measuring …

Integrated Transcriptome Analysis Reveals Molecular Subtypes and ceRNA Networks in Multiple Sclerosis

C Ji, L Ding, F Jia, Z Zhang, C Long - … and Neuromuscular Disease, 2024 - Taylor & Francis
Aim Multiple sclerosis (MS) is a chronic autoimmune disease affecting the central nervous
system (CNS). While extensively studied, its molecular subtypes and mechanisms remain …

Identification of shared pathogenic signatures of multiple sclerosis and chronic obstructive pulmonary disease: an integrated transcriptomic analysis of blood …

A Mokaram Doust Delkhah - Molecular Genetics and Genomics, 2025 - Springer
Patients with multiple sclerosis (MS) face a heightened risk of developing chronic obstructive
pulmonary disease (COPD). Despite this widely reported association, the pathogenic …